SEC Filings

Filing Description Date Filed Sorted Descending Size  
4 almenoff, june sherie 05-18-2012 27.4 KB  
8-K current report 05-15-2012 76.9 KB  
10-Q quarterly report 05-07-2012 226.6 KB  
8-K current report 05-03-2012 59.0 KB  
4 woodworth, marshall h 04-11-2012 27.5 KB  
4 mcintyre, gail frances 04-11-2012 27.5 KB  
4 covington, paul s 04-11-2012 27.5 KB  
4/A almenoff june sherie 04-11-2012 24.9 KB  
DEFA14A definitive proxy statement 04-11-2012 25.1 KB  
DEF 14A definitive proxy statement 04-11-2012 252.6 KB  
DEFA14A definitive proxy statement 04-11-2012 25.1 KB  
DEF 14A definitive proxy statement 04-11-2012 252.6 KB  
SC 13G/A amended statement of beneficial ownership 04-10-2012 89.9 KB  
4 eshelman, fredric n 03-19-2012 27.5 KB  
4 eshelman, fredric n 03-15-2012 28.2 KB  
4/A eshelman fredric n 03-15-2012 24.8 KB  
SC 13D/A amended general statement of beneficial ownership 03-13-2012 34.8 KB  
4 eshelman, fredric n 03-12-2012 28.9 KB  
4 eshelman, fredric n 03-07-2012 28.1 KB  
10-K annual report 03-07-2012 808.2 KB  
Showing 1-20 of 145 Page: 1 2 3 ... 8  Next 20
Investor Relations
Contact:

Sailash Patel
Vice President, Strategic Development
Furiex Pharmaceuticals, Inc.
+1 919 456 7814

Stock Quote (NASDAQ: FURX)
Price:
15.76
Change:
+ 1.00
Day High:
15.81
Day Low:
14.65
Volume:
149,900
4:00 PM ET on 05-18-2012
Delayed ~20 min. By eSignal.